Gastroenteritis (Gastrointestinal) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis – Drugs In Development, 2021, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape.

Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 3, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gastroenteritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Gastroenteritis (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Gastroenteritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Gastroenteritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Gastroenteritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Gastroenteritis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Gastroenteritis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Gastroenteritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Allakos Inc

Cocrystal Pharma Inc

Kyowa Kirin Co Ltd

Lanzhou Institute of Biological Products Co Ltd

Medicago Inc

Novo Medi Sciences Pvt Ltd

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

UMN Pharma Inc

Vaxart Inc

Table of Contents

Table of Contents

Introduction

Gastroenteritis - Overview

Gastroenteritis - Therapeutics Development

Gastroenteritis - Therapeutics Assessment

Gastroenteritis - Companies Involved in Therapeutics Development

Gastroenteritis - Drug Profiles

Gastroenteritis - Dormant Projects

Gastroenteritis - Discontinued Products

Gastroenteritis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Gastroenteritis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Gastroenteritis – Pipeline by Allakos Inc, 2021

Gastroenteritis – Pipeline by Cocrystal Pharma Inc, 2021

Gastroenteritis – Pipeline by Kyowa Kirin Co Ltd, 2021

Gastroenteritis – Pipeline by Lanzhou Institute of Biological Products Co Ltd, 2021

Gastroenteritis – Pipeline by Medicago Inc, 2021

Gastroenteritis – Pipeline by Novo Medi Sciences Pvt Ltd, 2021

Gastroenteritis – Pipeline by RedHill Biopharma Ltd, 2021

Gastroenteritis – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Gastroenteritis – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Gastroenteritis – Pipeline by UMN Pharma Inc, 2021

Gastroenteritis – Pipeline by Vaxart Inc, 2021

Gastroenteritis – Dormant Projects, 2021

Gastroenteritis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Gastroenteritis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports